FibroGen nnounces first patient dosed in ZEPHYRUS, phase 3 clinical trial of pamrevlumab
FibroGen announced dosing of the first patient in the ZEPHYRUS Phase 3 clinical study of pamrevlumab in patients with idiopathic pulmonary fibrosis. ZEPHYRUS is a randomized, double-blind, placebo-controlled, multi-center Phase 3 trial designed to evaluate efficacy and safety of pamrevlumab. July 22, 2019